Study summary · research use only
Glutathione in HIV-Associated Neurocognitive Disorders
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This review discusses trials of glutathione supplementation in humans with HIV-associated neurocognitive disorders (HAND), conditions the authors note often persist despite antiretroviral therapy and are linked to oxidative stress from viral and inflammatory mechanisms. The authors report disease-specific results across the reviewed trials and, for diseases lacking completed trials, offer predicted responses to glutathione supplementation based on mechanisms described in the literature. The authors state it is not possible to conclude that all HAND conditions would benefit from glutathione's antioxidant properties, and that potential effects of supplementation likely differ depending on the specific HIV-associated neurocognitive disease.
Abstract
A large portion of patients with Human Immunodeficiency Virus (HIV) have neurologic sequelae. Those with better-controlled HIV via antiretroviral therapies generally have less severe neurologic symptoms. However, for many patients, antiretrovirals do not adequately resolve symptoms. Since much of the pathogenesis of HIV/AIDS (Autoimmune Deficiency Syndrome) involves oxidative stress either directly, through viral interaction, or indirectly, through inflammatory mechanisms, we have reviewed relevant trials of glutathione supplementation in each of the HIV-associated neurocognitive diseases and have found disease-specific results. For diseases for which trials have not been completed, predicted responses to glutathione supplementation are made based on relevant mechanisms seen in the literature. It is not sufficient to conclude that all HIV-associated neurocognitive disorders (HAND) will benefit from the antioxidant effects of glutathione supplementation. The potential effects of glutathione supplementation in patients with HAND are likely to differ based on the specific HIV-associated neurocognitive disease.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.